Phase 3
Completed N=221
A Controlled Study to Determine the Efficacy and Safety of CL-108 5 mg for Acute Pain and the Prevention of OINV
Source: ClinicalTrials.gov NCT03657810 ↗Enrolled (actual)
221
Serious AEs
0.4%
Results posted
Mar 2023
Primary outcomePrimary: Percentage of Participants With OINV Over 48 Hours — 8; 31; 4 Participants — p=<0.001
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
To determine the analgesic efficacy of CL-108 5 mg by comparison with placebo and the anti-emetic efficacy of CL-108 5 mg by comparison with hydrocodone 5 mg/acetaminophen 325 mg.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants With OINV Over 48 Hours |
8; 31; 4 | <0.001 sig |
| PRIMARY The Sum of Pain Intensity Differences (on PI-NRS) Over 48 Hours (SPID48) |
108.5; 94.8; 78.7 | 0.052 |
| SECONDARY Percentage of Patients With Complete Absence of OINV (no Nausea, no Vomiting, and no Use of Anti-emetic Medication) Over 48 Hours |
50; 34; 27 | — |
| SECONDARY Percentage of Patients With Any Vomiting Over 48 Hours |
3; 19; 2 | — |
| SECONDARY Percentage of Patients With Any Nausea Over 48 Hours |
36; 55; 15 | — |
| SECONDARY Percentage of Patients With Any Nausea or Vomiting Over 48 Hours |
37; 55; 16 | — |
| SECONDARY Percentage of Patients With Any Post-discharge Nausea and Vomiting (PDNV) |
9; 12; 6 | — |
| SECONDARY Number of Doses of Study Medication Taken Over Days 3to7 |
10.0; 8.4; 6.2 | — |
| SECONDARY Number of Doses of Study Medication Taken Per Day Over Days 3to7 |
3.0; 2.4; 2.1; 2.1; 1.9; 1.4 | — |
Eligibility Criteria
Inclusion Criteria
- Informed consent: Signed informed consent form obtained at screening prior to any procedures being performed.
- Gender: Male or non-pregnant and non-lactating female.
- Age: 18 years or older at time of consent.
- Foot condition: Primary unilateral first metatarsal bunionectomy (osteotomy and internal fixation) with no additional collateral procedures.
- Pain Severity: Presence of moderate or severe pain on a categorical pain intensity scale at Baseline
- Pain Confirmation: On the 0-10 numerical pain intensity scale at Baseline.
- Diary Completion: Be willing and able to record safety and efficacy ratings in the Diaries.
- Safe Transportation Home: Patient must have arrangements for transportation home from the research center accompanied by a responsible adult.
Exclusion Criteria
- Medical condition: Presence of a serious medical condition, intolerance to NSAIDs, or any other medical condition which, in the opinion of the Investigator, makes the patient unsuitable for participation.
- Infection: Acute infection of the surgical site at the time of surgery that could confound post-surgical evaluation.
- Drug Allergy: History of hypersensitivity to an opioid drug (such as hydrocodone), promethazine, acetaminophen, NSAID (such as ibuprofen or aspirin), midazolam, propofol, mepivacaine, ropivacaine or ketorolac.
- Confounding and Contraindicated Drugs: Other than protocol-permitted medications administered pre-operatively or during surgery: use within 14 days before or during the surgical procedure of any systemic corticosteroid or use within 24 hours or during the surgical procedure of any confounding prescription or non-prescription drug or any drug contraindicated with hydrocodone, acetaminophen, or promethazine. [Note: Antibiotic for endocarditis prophylaxis (except if known to cause nausea) and aspirin (ASA) ≤ 325 mg for cardiovascular prophylaxis are permitted during the study.] History of consuming more than 2 alcoholic drinks per day every day for the last month or a positive urine test for opiates, benzodiazepines, barbiturates, tetrahydrocannabinol, methamphetamines, cocaine, oxycodone, cotinine at screening or the morning of surgery will exclude the patient from the trial.
- Investigational Drug Use: Use of an investigational drug within the past 30 days.
- Participated in Study: Previous participation in this study.
- Pregnancy, Lactation: Women who are pregnant or lactating.
- Compliance: Inability to swallow capsules whole.
- Participant relationship: Employee at the research center, employee of the Principal Investigator, Sub-Investigators, or sponsor or relative of the Investigator, Sub-Investigators or research staff who is involved in this study.
Data sourced from ClinicalTrials.gov (NCT03657810). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.